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Available online xxxxA critical research goal is to identify modifiable risk factors leading to functional disabilities in young psychiatric
patients. The authors developed a multidimensional trans-diagnostic predictive model of functional outcome in
patients with the recent-onset of a psychiatric illness.
Baseline clinical, psychosis-risk status, cognitive, neurological-soft-signs measures, and dopamine-related-gene
polymorphisms (DRD1-rs4532, COMT-rs165599, and DRD4-rs1800955) were collected in 138 young non-psy-
chotic outpatients.
116 individuals underwent follow-up (mean = 2.2 years, SD = 0.9) examination. A binary logistic model was
used to predict low-functioning status at follow-up as defined by a score lower than 65 in the social occupational
functioning assessment scale.
A total of 54% of patients experiences low functioning at follow-up. Attention, Avolition, andMotor-Coordination
subscale were significant predictors of low-functioning with an accuracy of 79.7%. A non-significant trend was
found for a dopamine-related-gene polymorphism (DRD1-rs4532). The model was independent of psychotic-
risk status, DSM-diagnosis, and psychotic conversion.
A trans-diagnostic approach taking into account specific neurocognitive, clinical, and neurological information
has the potential to identify those individuals with low-functioning independent of DSM diagnosis or the level
of psychosis-risk.
Specific early interventions targetingmodifiable risk factors and emphasize functional recovery in young psychi-
atric samples, independent of DSM-diagnosis and psychosis-risk, are essential.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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“Genetics”1. Introduction
Functional disabilities are common amongmental disorders (Kessler
et al., 2009). Even though psychotic spectrum disorders (PSDs) (Lee et
al., 2015) are traditionally associated with greater functional disabilitythis article represents original
as not being considered for
thor.
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s. (2016), http://dx.doi.org/1than affective and anxiety disorders (Plaisier et al., 2010), a 2009 update
from theWorld Mental Health Survey shows that severe functional im-
pairments are not unique to the psychosis-spectrum (Kessler et al.,
2009). A critical research goal is therefore to identify and intervene to
target modifiable risk factors leading to long-term disability not only
in PSDs, but in the whole spectrum of psychiatric disorders (Lee et al.,
2015).
Studies of adults with chronic mental illness show that multiple fac-
tors are linked to functional decline across traditional diagnostic bound-
aries (Iosifescu, 2012). Baseline impairments in functioning (Carrión et
al., 2013), cognition and theory ofmind (Lee et al., 2015), aswell as neu-
rological, neurophysiological and brain structural abnormalitiesme in young patientswith a recent-onset psychiatric disorder: Beyond
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2 A. Minichino et al. / Schizophrenia Research xxx (2016) xxx–xxx(Dazzan and Murray, 2002), have been associated with future poor
functional outcomes in schizophrenia (Chan et al., 2015), mood ,
anxiety, and personality disorders (Plaisier et al., 2010; Dazzan and
Murray, 2002).
Findings in adult populations are often tempered by chronic ill-
ness and prolonged treatment (Allott et al., 2011). Research efforts
targeting functional recovery should thus be focused on the earlier
phases of psychiatric disorders, when individuals are less impaired
and more amenable to therapeutic interventions (Fusar-Poli et al.,
2014).
So far, most studies investigating functional outcome in early-onset
psychiatric syndromes pertain to individuals with an “At-Risk Mental
State” (ARMS) for psychosis (Carrión et al., 2013). Approximately 1/3
of ARMS individuals develops a psychotic episode (Fusar-Poli et al.,
2014). However, many of them remain functionally impaired indepen-
dently of psychosis transition, highlighting the need for a broad, trans-
diagnostic approach to functional outcome, cutting across the psychotic
spectrum (Carrión et al., 2013).
Given the relevance of functional outcome in psychiatry, and the
evidence that disability is not unique to psychotic disorders (Kessler
et al., 2009; Lee et al., 2015), research on early predictors of function-
al decline should target the full range of recent-onset psychiatric
syndromes.
Specifically: negative and disorganized symptoms, neurological soft
signs, theory of mind, neurocognition, and baseline functioning abnor-
malities have been consistently detected in young psychiatric outpa-
tients and related to future outcomes independent of DSM diagnosis
and psychosis-risk status (Lee et al., 2015; Plaisier et al., 2010;
Iosifescu, 2012; Francesconi et al., 2016; Minichino et al., 2016a).
These domains may represent optimal trans-categorical predictors of
functioning and thus new promising therapeutic targets.
Some of these domains, such as neurocognitive and theory of mind
impairments, seem to be linked to functional disability regardless of
the expression of symptoms (Francesconi et al., 2016; Lee et al., 2015),
as they are also expressed in the unaffected relatives of patients with
mental illness (Tsang et al., 2015). These findings suggest that genetic
factors could contribute to future outcome (Tsang et al., 2015) possibly
as a mediating variable. Several susceptibility genes are associated with
cellular mechanisms linked to cognitive processing domains that are
predictors of functional outcome in ARMS studies (Plaisier et al.,
2010). In particular, dopamine-related gene polymorphisms associated
with dopaminergic function in prefrontal cortex, such as the Dopamine
Receptor D1 (DRD1) rs4532, the Catechol-O-Methyltransferase (COMT)
rs165599, and the Dopamine Receptor D4 (DRD4) rs1800955, have
been linked to specific cognitive impairments (e.g. verbal fluency and
working memory), in both relatives and patients across different diag-
nostic groups (Tsang et al., 2015).
The present study aimed to identify trans-diagnostic baseline pre-
dictors of low functional outcome, consistent with the trans-diagnostic
approach of the Research Domain Criteria (RDoC) initiative from the
National Institute of Mental Health (Cuthbert and Insel, 2013), in a
large, prospective, longitudinal sample of help-seeking adolescents
and young adults treated in secondary mental health services.
We addressed the following questions: (A) What are the functional
trajectories of young patients with a recent-onset psychiatric disorder
with 2 to 3 years of follow-up? (B) How are baseline functioning, cogni-
tion, theory of mind, genetic and neurological variables associated with
long term functioning in these individuals? (C) Is prediction of function-
al outcome independent of (i) ARMS status; (ii) psychosis transition;
and (iii) psychiatric diagnosis?
2. Methods
The institutional review board of Sapienza, University of Rome ap-
proved the study. Written informed consent (with assent from partici-
pants b18) was obtained from all participants.Please cite this article as:Minichino, A., et al., Prediction of functional outco
the traditional diagnostic cla..., Schizophr. Res. (2016), http://dx.doi.org/12.1. Participants and recruitment strategy
Subjects were recruited in three different clinics (Rome, Italy) that
provide secondary general mental health care for adolescents and
young adults. Patients who seek help in these clinical sites do not differ
in terms of clinical anddemographic characteristics. For 17months (No-
vember 2011 to June 2013), the attending psychiatrists screened pa-
tients for the following exclusion criteria: current or past diagnosis of
psychosis-spectrum or bipolar disorder; present or past diagnosis of a
brief psychotic disorder with a duration equal to or N1 week; diagnosis
of mental retardation or other cognitive disorders, psychiatric disorders
due to a somatic factor or related to psychotropic substances; drug
abuse within the last 3 months; central nervous system disorders; and
history or current use of antipsychotic medications. After this first
screening, patients aged 17–35 years old, were referred to a group of
three trained interviewers. Referred individuals underwent the Struc-
tural Clinical Interview for DSM-IV Axis I (SCID-I) and II (SCID-II) disor-
ders to certify exclusion criteria and diagnoses. Raterswere experienced
research clinicianswho demonstrated adequate reliability at routine re-
liability checks.2.2. Baseline assessment
Clinical information was obtained through the SCID-I and II and the
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987). The
Comprehensive Assessment of At-Risk Mental States (CAARMS) inter-
viewwas used to identify (Yung et al., 2005) ARMS+and ARMS− indi-
viduals. The CAARMS inter-rater reliability was assessed in 34 subjects
(ICC = 0.93). NSS were assessed with the Neurological Evaluation
Scale (NES) (Buchanan and Heinrichs, 1989), which comprises the fol-
lowing subscales: “sensory-integration”, “motor-coordination”, “se-
quencing of complex motor acts”, and “others”. Items of the NES are
scored on a three-point scale from 0 = no abnormality to 2 = marked
impairment.
Neurocognitionwas assessedwith the Repeatable Battery for theAs-
sessment of Neuropsychological Status (RBANS) (Randolph et al., 1998).
The RBANS comprises five index scores (Attention, Immediate and De-
layedMemory, Language and Visuospatial indices) and a total score. So-
cial cognitive ability was assessed using the following scales: the
Reading the Mind in the Eye Test (Baron-Cohen et al., 1997), the Faux
Pas (Stone et al., 1998) test and the Theory of Mind Assessment Scale
(Bosco et al., 2009). Baseline Functioning was assessed using the Global
Assessment of Functioning scale (GAF) (Hall, 1995), the Social and Oc-
cupational Functioning Assessment Scale (SOFAS) (Yung et al., 2005),
and the Life Skills Profile-39 items (Rosen et al., 1989). The LSP-39 com-
prises 39 items grouped in 5 subscales: Self-Care, Responsibility, Com-
munication, Non-Turbulence, and Social-contact. A total score can be
obtained by summing the responses for all items with low scores
reflecting high level of skills. The LSP-39 total score has been consistent-
ly used as a proxy of real-world living skills (Puig et al., 2013).2.2.1. Genetic
Using salivary samples, the DRD1 rs4532 (−48A/G), the COMT
rs165599 and the DRD4 rs1800955 (C-521T) polymorphisms were
evaluated in a subgroup of participants (n= 74) (see eAppendix).2.3. Follow-up procedure
Functional and clinical data were collected through a single fol-
low-up face to face interview that took place at a mean time of
2.2 years from the baseline assessment. Transition to psychosis was
defined according to previously operationalized criteria (Yung et
al., 2005).me in young patientswith a recent-onset psychiatric disorder: Beyond
0.1016/j.schres.2016.12.019
Fig. 1. Flow chart showing the different phases of the recruitment strategy and the follow-
up at amean time of 2.2 years. Abbreviation: SCID-I and II: structured clinical interview for
DSM-IV Axis I and II disorders.
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The primary outcome variable for this studywas functional outcome
at the follow-up visit as defined by the SOFAS.
This scale was used given its wide clinical and consistent use as pri-
marymeasures of functional outcome in several studies andmeta-anal-
yses on ARMS individuals (Cotter et al., 2014; Fusar-Poli et al., 2015),
thus potentially facilitating interpretation of findings and future replica-
tion studies.
The overall sample was divided in two groups: Low Functional (LF)
and High functional (HF) outcome.
LF andHFwere defined as a current score of 65 andhigher (HF) or 64
and lower (LF) in the SOFAS during the follow-up examination.
The group split at SOFAS score of 65 was chosen according to previ-
ously published methods (Allen et al., 2015). The 60–70 range corre-
sponds to the presence of “some difficulty in social or occupational
functioning but [the subject] generally functions pretty well”. SOFAS
scores below 60 indicate “moderate to severe impairment”, whilst
sores above 70 correspond to “slight impairment to good function”.
Also, 65 was the median SOFAS value for the overall sample during
the follow-up assessment.
The cut-off valuewas chosen following a consistent body of previous
literature.
An additional measure of functional outcome, as defined by the LSP-
39 total score was also collected at follow-up.
2.5. Statistical analysis
All analyses were conducted using SPSS version 21.0. Comparison of
baseline characteristics was performed with ANOVAs for continuous
variables and Pearson χ2 tests for categorical variables (2-tailed,
P b 0.05).
A binary logistic model was constructed to predict functional out-
come according to the SOFAS-based definition of functioning at fol-
low-up.
Based on previous evidence, predictor variables were generated
within the following domains: demographic and clinical (Addington
et al., 2015), neurocognitive (Meyer et al., 2014), theory of mind (Lee
et al., 2014), NSS (Chan et al., 2009) and functioning at baseline
(Carrión et al., 2013) (eTable1), and selected in several steps (Hosmer
et al., 2013; Carrión et al., 2013) (eAppendix).
The final models were adjusted for the possible confounding effects
of (i) psychosis transition at follow-up; (ii) ARMS status; (iii) DSM-IV
diagnosis at baseline; (iv) PANSS general subscale score at baseline;
(v) antipsychotic and psychotherapy intervention at baseline and fol-
low-up; (vi) drug/alcohol abuse at follow-up; (vii) gender; (viii)
SOFAS and LSP-39 total score at baseline.
3. Results
3.1. Participants
A total of 140 participants were referred to the study. Two individ-
uals fulfilled SCID-I criteria for substance abuse, and were excluded.
The remaining 138 individuals underwent CAARMS interview. A total
of 67 ARMS+ and 71 ARMS−were enrolled in the study.
Of the 138 subjects enrolled in the study, 22 (15.9%) were lost and
116 (84.1%) completed the follow-up clinical evaluation, (Fig. 1). Pa-
tients with follow-up information did not differ significantly from
those lost to follow-up in any of the variables investigated.
Table 1 shows demographic, clinical, cognitive and NSS information
of the HF and LF groups.
At baseline, the LF group had a higher prevalence of comorbid anxi-
ety and mood disorders compared to the HF. Negative symptoms and
functional impairments at baseline were significantly greater in the LF
group, which was also characterized by a higher transition to psychosisPlease cite this article as:Minichino, A., et al., Prediction of functional outco
the traditional diagnostic cla..., Schizophr. Res. (2016), http://dx.doi.org/1rate at follow-up (Table 1). Of note, the proportion of individuals who
met ARMS criteria did not differ between the HF and LF groups.
During the follow-up period, therewas a significant difference in the
percentage of change in functioning between the two outcome groups.
Patients in the HF group showed an improvement in SOFAS and LSP-39
total score (+12% and+7%, respectively), while the LF group showed a
relevant functional decline (−21% and−17%).
At baseline, significantly lower scores on the RBANS Attention, Im-
mediate Memory and Delayed Memory indices were found in LF indi-
viduals, as well as higher levels of motor- coordination signs (Table 1).
3.2. Correlation among measures of functional outcome at follow-up
Compared to the HF group, the LF group showed significantly lower
scores in the follow-up LSP-39 total scores (Table 1).
At follow-up, SOFAS scoreswere significantly correlatedwith LSP-39
total scores (r=−0.57: P ≤0.001).
3.3. Treatment
Table 1 reports baseline and follow-up medications of the HF and LF
groups. At follow-up, the percentage of patients in the LF group receiv-
ing antipsychotics (P b 0.01), mood stabilizers (P b 0.05) anxiolytics
(P b 0.05), and psychotherapy (p b 0.01) was significantly higher than
at baseline. The HF group, as well, received more antipsychotics
(P b 0.01) and psychotherapy (P b 0.01) compared to baseline. These
data indicate active therapeutic interventions during the follow-up pe-
riod in both LF and HF individuals. Finally, 13.8% of the sample devel-
oped a drug dependence/abuse diagnosis at follow-up (P b 0.01), but
no differences were found between HF and LF.
3.4. Prediction of functional outcome
TheRBANSAttention Index, theCAARMSAvolition item, and theNSS
Motor-Coordination subscale were significant predictors of LF outcome
(Table 2). The final multivariable model accounted for 35% of theme in young patientswith a recent-onset psychiatric disorder: Beyond
0.1016/j.schres.2016.12.019
Table 1
Demographic, clinical, genetic, cognitive and neurological soft signs variables in the two outcome groups (LF and HF).
Characteristic LF (n = 63) HF (N = 53) P value
Demographic
Age,
mean (SD)
24.38 (3.78) 23.94 (3.47) 0.53
Education, years,
mean (SD)
11.15 (3.05) 10.77 (2.78) 0.50
Male
N, (%)
35 (57.4) 25 (48.1) 0.35
Clinical
ARMS+,
N, (%)
30 (47.6) 24 (45.3) 0.85
Transition to psychosis,
N, (%)
16 (25.4) 5 (9.6) 0.03
CAARMS,
mean (SD)
Positive symptoms 7.68 (5.84) 7.11 (5.94) 0.61
Negative symptoms 5.79 (1.77) 4.55 (1.82) b0.001
Emotional disturbances 4.73 (3.14) 4.66 (3.15) 0.90
Cognitive change 5.00 (1.73) 4.891 (1.61) 0.72
Behavioral change 11.05 (2.07) 10.66 (2.16) 0.33
PANSS,
mean (SD)
Positive symptoms 13.16 (3.87) 13.38 (2.77) 0.74
Negative symptoms 14.31 (3.03) 14.50 (3.37) 0.77
General symptoms 37.97 (6.18) 37.77 (7.52) 0.87
DSM-IV diagnosis,
N, (%)
Mood disorders a 24 (38.2) 25 (47.1) 0.32
Anxiety disorder b 4 (6.4) 8 (15.1) 0.12
Personality disorder c 10 (15.8) 10 (18.9) 0.67
Comorbidity of mood and anxiety disordersd 25 (39.6) 10 (18.9) 0.02
Duration of illness, years,
mean (SD)
2.16 (0.88) 2.14 (0.89) 0.87
Baseline medications,
N, (%)
No medications 5 (8.2) 6 (11.5) 0.75
Antipsychotics None None
Antidepressants 45 (73.8) 31 (59.6) 0.15
Anxiolytics 35 (55.5) 24 (45.2) 0.27
Mood stabilizers 16 (26.2) 10 (19.2) 0.50
Follow up medications,
N, (%)
No medications None 11 (20.7) b0.001
Antipsychotics 28 (44.4) 14 (26.4) 0.04
Antidepressants 41 (65.1) 25 (47.2) 0.06
Anxiolytics 48 (76.2) 13 (24.5) b0.001
Mood stabilizers 33 (52.4) 11 (20.8) b0.001
Psychotherapy (N5 sessions),
N (%)
Baseline none none
Follow up 18 (28.5) 13 (24.5) 0.62
Baseline functioning
Unemployed/not in education,
N, (%)
30 (50.0) 23 (44.2) 0.57
GAF,
mean (SD)
62.84 (9.48) 63.75 (8.49) 0.59
SOFAS
Mean (SD)
64.60 (10.45) 65.00 (9.30) 0.83
LSP-39,
mean (SD)
Self-care 19.80 (5.98) 17.81 (4.21) 0.04
Non turbulence 24.00 (5.53) 22.77 (5.09) 0.22
Social contact 11.39 (3.36) 10.62 (2.39) 0.17
Communication 11.02 (2.89) 10.31 (2.49) 0.17
Responsibility 10.15 (2.18) 9.44 (1.75) 0.06
Total score 76.36 (13.91) 70.94 (9.02) 0.02
Follow up functioning
SOFAS
mean (SD)
50.03 (7.1) 70.94 (6.0) b0.001
LSP-39 total score
mean (SD)
86.84 (9.7) 74.91 (9.5) b0.001
Genetics [N with analyzable data = 74] [N = 41] [N = 33]
DRD1 rs4532 genotype,
N (%)
4 A. Minichino et al. / Schizophrenia Research xxx (2016) xxx–xxx
Please cite this article as:Minichino, A., et al., Prediction of functional outcome in young patientswith a recent-onset psychiatric disorder: Beyond
the traditional diagnostic cla..., Schizophr. Res. (2016), http://dx.doi.org/10.1016/j.schres.2016.12.019
Table 1 (continued)
Characteristic LF (n = 63) HF (N = 53) P value
AA 16 (39.1) 22 (66.7)
AG 19 (46.3) 10 (30.3) 0.04
GG 6 (14.6) 1 (3.0)
Presence of the G allele,
N (%)
AG or GG 25 (60.9) 11 (33.3) 0.02
DRD1 rs4532 allele frequency,
N (%)
A allele 51 (62.2) 54 (81.8) b0.001
G allele 31 (37.8) 12 (18.2)
DRD4 rs1800955 genotype
N, (%)
CC 15 (36.6) 15 (45.5) 0.29
CT 15 (36.6) 14 (42.4)
TT 11 (26.8) 4 (12.1)
Presence of the T allele
N, (%)
CT or TT 26 (63.4) 18 (54.5) 0.44
DRD4 rs1800955 allele frequency,
N, (%)
C Allele 45 (54.8) 44 (66.7) 0.14
T Allele 37 (45.2) 22 (33.3)
COMT rs165599 genotype,
N (%)
AA 21 (51.2) 19 (57.6) 0.18
AG 16 (39.0) 14 (42.4)
GG 4 (9.8) 0 (0.0)
Presence of the G allele,
N (%)
AG or GG 20 (48.8) 14 (42.4) 0.58
COMT rs165599 alleles,
N (%)
A allele 58 (70.7) 52 (78.8) 0.26
G allele 24 (29.3) 14 (21.2)
Neurocognition
RBANS,
mean (SD)
Immediate memory index 92.70 (10.15) 97.19 (9.59) 0.02
Language index 89.79 (8.84) 89.77 (8.55) 0.99
Visuospatial index 91.41 (8.90) 92.62 (8.18) 0.45
Attention index 80.92 (8.32) 87.42 (7.87) b0.001
Delayed memory index 89.14 (8.10) 93.49 (8.24) b0.001
Total Score 81.98 (7.93) 86.30 (8.91) b0.001
Theory of mind
Faux Pas,
mean (SD)
Faux Pas questions 17.27 (1.81) 17.58 (1.43) 0.31
Faux Pas controls 38.78 (1.15) 38.74 (1.00) 0.84
RMET,
mean (SD)
25.58 (3.08) 26.02 (2.80) 0.44
Th.o.m.as.,
mean (SD)
Thomas A 33.47 (6.63) 35.18 (5.90) 0.15
Thomas B 28.71 (8.53) 29.08 (7.75) 0.81
Thomas C 25.77 (7.21) 28.02 (6.46) 0.08
Thomas D 28.32 (7.96) 28.24 (7.73) 0.95
Neurological soft signs
NES,
mean (SD)
Motor coordination 1.97 (1.34) 1.09 (1.09) b0.001
Sensory integration 1.54 (1.17) 1.26 (1.02) 0.18
Sequencing of complex motor acts 1.52 (1.45) 1.40 (1.23) 0.61
Others 1.83 (1.61) 1.45 (1.32) 0.18
Total score 6.86 (4.50) 5.21 (2.90) 0.02
Abbreviations: HF, High Functioning; LF, Low Functioning; ARMS+, Positive to At Risk Mental State; CAARMS, Comprehensive Assessment of At Risk Mental State ; PANSS, Positive And
Negative Syndrome Scale; DSM- IV, Diagnostic and Statistical Manual of Mental Disorders 4th Edition; GAF, Global Assessment of Functioning; LSP-39, Life Skill Profile 39 items; SOFAS,
Social andOccupational FunctioningAssessment Scale; DRD1, Dopamine ReceptorD1; DRD4, Dopamine receptorD4; COMT, Catechol-O-methyltransferase; RBANS, Repeatable Battery for
the Assessment of Neuropsychological Status; RMET, Reading the Mind Eyes in the Test; Th.o.m.a.s., Theory Of Mind Assessment Scale; NES, Neurological Evaluation Scale.
p b 0.05
a DSM-IV diagnoses: Major Depressive Disorder (MDD), Adjustment Disorder with Depressed Mood, Adjustment Disorder with Anxiety.
b DSM-IV diagnoses: Generalized Anxiety Disorder (GAD), Panic Disorder, Obsessive Compulsive Disorder.
c DSM-IV diagnoses: Borderline Personality Disorder.
d DSM-IV diagnoses: MDD and GAD, MDD and OCD, Adjustment Disorder with Depressed Mood and Anxiety.
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Table 2
Logistic regression model predicting functional outcome in the whole group of patients (n= 116).
Predictor variable β SE Wald ×2 Hazard ratio P value AUCa (SE) [95% CI] R2N Sensitivity Specificity
Attention (RBANS) 0.079 0.03 8.34 1.08 0.004
Motor coordination (NES) −0.547 0.21 6.79 0.57 0.009 0.797 (0.041)
[0.717–0.878]
0.350 0.730 0.679
Avolition (CAARMS) −0.744 0.26 8.02 0.47 0.005
Abbreviations: RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; NES, Neurological Evaluation Scale; CAARMS, Comprehensive Assessment of At Risk Mental
State; AUC, Area Under the Curve; R2N, Nagelkerke pseudo R2 statistic; SE, Standard Error.
a The AUC values can range from 0.5 (indicates that an instrument can discriminate between groups no better than chance) to 1.0 (represents perfect discriminatory performance) and
can be interpreted using the following categories: acceptable = 0.70, good = 0.80, and excellent = 0.90.
6 A. Minichino et al. / Schizophrenia Research xxx (2016) xxx–xxxvariance (R2N = 0.350) and showed a good discriminative ability, with
an AUC of 79.7% (95% CI, 71.7–87.8; P b 0.001), a sensitivity of 73.0% and
specificity of 67.9% (eFigure1).
Prediction of functional outcome in a subgroup of individuals (n= 74)
with the analyzable genetics data.
Table 1 shows the prevalence of the DRD1 rs4532, COMT rs165599
and DRD4 rs1800955 polymorphisms in the subgroup of patients with
analyzable data (n = 74). There were no significant differences be-
tween LF and HF groups in terms of expression of COMT rs165599 and
DRD4 rs1800955 polymorphisms. In contrast, the AG and GG genotypes
of the DRD1 rs4532 were significantly more expressed in the LF than in
the HF group (P b 0.05) (Table 1).
The “presence of the G allele (DRD1)” (i.e. expression of the AG or
GG genotype) was thus added to the set of three variables previously
identified, with the aim of evaluating whether genetic data could im-
prove the final predictive model of functional outcome.
Given the smaller number of participants (n=74) available for this
analysis, we decided to report also non-significant statistical trend re-
sults (P b 0.10) for the final step of the regression.
We used this approach, even if limited by this liberal threshold, be-
cause it could represent a relevant hypothesis-generating finding. In-
deed: 1) there is a lack of studies investigating the impact of clinical-
genetic interactions on prognostic outcomes in psychiatry; and 2)
given the young age and the relatively short duration of illness charac-
terizing our sample, our findings may be useful for future studies inves-
tigating early modifiable risk factors of functional disabilities.
Using this approach, the Attention Index, Avolition and “presence of
the G allele (DRD1)” predicted LF with an accuracy of 81.9% (Table 3)
(95% CI, 72.6–91.3; P b 0.001; eFigure 2), a sensitivity of 75.6% and spec-
ificity of 72.7%. The “presence of the G allele (DRD1)” entered in the
model with a significance level of 0.058.
The final model accounted for 39% of the variance (R2N = 0.394).
In both the multivariable models (with and without genetic find-
ings), the identified predictive variables continued to predict functional
outcome even after adjusting for potential confounding variables
(eTable2), including ARMS status, ultimate conversion status, and
DSM-IV diagnosis.
The Attention Index, Avolition and “presence of the G allele (DRD1)”
were significant predictors of LF (Table 3). The final model accounted
for 39% of the variance (R2N = 0.394). The overall predictive ability of
this model was higher compared to the previous one, with an AUC of
81.9% (95% CI, 72.6–91.3; P b 0.001; eFigure 2), a sensitivity of 75.6%Table 3
Logistic Regression Model Predicting Functional Outcome in a subgroup of patients (n= 74) w
Predictor Variable β SE Wald ×2 Hazard Rati
Attention (RBANS) 0.078 0.03 5.11 1.08
Presence of the G allele (DRD1) −1.085 0.57 3.60 0.34
Avolition (CAARMS) −0.946 0.35 7.14 0.38
Abbreviations: RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; DR
AUC, Area Under the Curve; R2N, Nagelkerke pseudo R2 statistic; SE, Standard Error.
a The AUC values can range from 0.5 (indicates that an instrument can discriminate between
can be interpreted using the following categories: acceptable = 0.70, good = 0.80, and excelle
Please cite this article as:Minichino, A., et al., Prediction of functional outco
the traditional diagnostic cla..., Schizophr. Res. (2016), http://dx.doi.org/1and specificity of 72.7%. In both themultivariable models, the identified
predictive variables continued to predict functional outcome even after
adjusting for potential confounding variables (eTable2), including
ARMS status, ultimate conversion status, and DSM-IV diagnosis.
Similar results were obtained with an alternative multivariable
model built using the LSP-39 total score as primarymeasure of function-
al outcome at follow-up (eModels).
4. Discussion
To the best of our knowledge, this is the first study using a broad
trans-diagnostic approach, to identify predictors of functional outcome
across recent onset psychiatric syndromes. Our sample was composed
of individuals who came to a youth mental health clinic for treatment,
did not meet criteria for a psychotic disorder and had different levels
of risk for psychosis. In contrast to other ARMS samples, our participants
were already diagnosed and treated for specific psychiatric disorders,
with mean illness duration of 2.1 years, suggesting greater and more
stable psychopathological severity. Our study yielded 4 relevant find-
ings. First, 48% of the patients were ARMS+, however, low functional
outcomewas independent of ARMS classification andDSM-IV diagnosis.
This confirms previousfindings that baseline positive symptoms are not
predictive of low functional outcome (Carrión et al., 2013), and suggests
that categorizing patients based on traditional classification systems is
not informative in regards to functional trajectories. Second, NSS,
neurocognitive performance and negative symptoms at baseline were
key predictors of LF during the early phases of different psychiatric syn-
dromes. Third, a genetic marker improved the predictive model, sug-
gesting that genetic markers may also have a relevant impact on
functional outcome. Fourth, LFwasnot entirely dependent on the devel-
opment of psychosis, further promoting the need for a broader trans-di-
agnostic approach in the field of functional recovery (Minichino et al.,
2016a; Minichino et al., 2016b; Lee et al., 2015).
Patients in the LF group showed baseline impairments on the RBANS
Attention, Immediate and Delayed indices, with Attention being a sig-
nificant predictor of functional outcome. Previous evidence suggests
that these indices assess similar constructs as more widely used
neurocognitive batteries (Hobart et al., 1999). Poor performance on
the RBANS Attention index has been shown to be associatedwith global
functioning in cohorts of chronic psychiatric patients independent of
the diagnosis (Carrión et al., 2013). The Attention index, composed of
a Digit span and a Coding task (Hobart et al., 1999), is a combinedith genetic available data.
o P value AUCa (SE) [95% CI] R2N Sensitivity Specificity
0.024
0.058 0.819 (0.048)
[0.726–0.913]
0.394 0.756 0.727
0.008
D1, Dopamine Receptor D1; CAARMS, Comprehensive Assessment of At Risk Mental State.
groups no better than chance) to 1.0 (represents perfect discriminatory performance) and
nt = 0.90.
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7A. Minichino et al. / Schizophrenia Research xxx (2016) xxx–xxxmeasure of processing speed and workingmemory (Nuechterlein et al.,
2004). In a real-world context, reduced reaction time and an impaired
ability to maintain and process information might affect global func-
tioning, for example reducing the ability to select and maintain conver-
sational topics (Dickinson et al., 2007).
The LF group was also characterized by higher levels of negative
symptoms, with Avolition being an independent predictor of functional
outcome. Negative symptoms have traditionally been associated with
schizophrenia spectrum disorders (Norman et al., 2015). However, a
growing body of evidence suggests that they are expressed in associa-
tion with LF across different psychiatric diagnoses (Minichino et al.,
2016a). Thus, it is not surprising that Avolition may represent a predic-
tor of functional outcome independent of the ARMS status and DSM-IV
diagnosis.
Greater motor-coordination abnormalities also made a significant
independent contribution to the prediction of functional outcome.
These results are consistentwith a recent study byMittal and colleagues
(Mittal et al., 2014), which provides evidence for a role of NSS in
predicting poor outcomes in ARMS individuals independent of psycho-
sis transition. The authors also showed that NSS predicted a longitudinal
decrease in the white matter integrity of the cerebello-thalamic tract
thatwas associatedwith higher levels of negative symptoms. Consistent
with the trans-diagnostic approach used in the current study, high
levels of NSS have been associated with specific neural network abnor-
malities, cognitive dysfunction, negative symptoms and low functioning
in both psychotic and non-psychotic individuals (Minichino et al.,
2016a; Dazzan and Murray, 2002).
The expression of motor coordination dysfunctions, neurocognitive
deficits, and negative symptoms can be related to overlapping brain
structural and functional connectivity changes (Mittal et al., 2014),
such as fronto-parietal (Chan et al., 2009) and cerebello-thalamo-pre-
frontal dysfunctions (Dazzan and Murray, 2002; Zhao et al., 2014;
Minichino et al., 2014). Consistently, the LF group showed a higher
prevalence of the G allele, which also showed a non-significant trend
in prediction of functional outcome in a subgroup of patients.
The −48A/G polymorphism is associated with a reduced binding
ability of DRD1 in the prefrontal cortex (PFC) (Beaulieu and
Gainetdinov, 2011), and with a reduced PFC activation during cognitive
tasks (Williams and Goldman-Rakic, 1995). Dysfunctions of DRD1 sig-
naling in the PFC have been proposed as a potential cause of NSS
(Russell et al., 2005), negative symptoms (Lynch, 1992) and
neurocognitive deficits (Tsang et al., 2015) in both schizophrenia
(Goldman-Rakic et al., 2004) and non-schizophrenia spectrum disor-
ders (Tsang et al., 2015). Furthermore, evidence suggests that the
DRD1 polymorphismmay lead to antipsychotic resistance independent
of the psychiatric diagnosis (Ota et al., 2012). It is possible that LF at fol-
low-up could be associated with the expression of the G allele and thus
with treatment resistance. This finding highlights the need for more
targeted pro-cognitive intervention in patients with low functional
trajectories.
The reduced binding ability of the DRD1 in the PFCmay trigger a cas-
cade of events leading to (i) NSS abnormalities; (ii) neurocognitive im-
pairments; (iii) greater levels of negative symptoms; and (iv)
antipsychotics resistance, defining the common thread that character-
izes those individuals with low functional outcome across diagnostic
categories. As previously highlighted, motor-coordination signs, pro-
cessing speed and working memory deficits, as well as severity of neg-
ative symptoms, have been related to shared neural vulnerabilities,
mainly involving the cerebello-thalamo-prefrontal network (Mittal et
al., 2014; Zhao et al., 2014), which is rich in DRD1 receptors. Young pa-
tients expressing these characteristics may benefit from specific inter-
ventions based on plasticity-based trainings or non-invasive brain
modulation techniques targeting this network (Minichino et al.,
2015). These non-pharmacological strategies may be particularly help-
ful in patients expressing the DRD1-rs4532 polymorphism, given its as-
sociation with antipsychotics resistance.Please cite this article as:Minichino, A., et al., Prediction of functional outco
the traditional diagnostic cla..., Schizophr. Res. (2016), http://dx.doi.org/1Finally, as mentioned in the Introduction, the approach used in the
current study (i.e., examining markers across different categories of re-
cent-onset psychiatric disorders) is consistent with the RDoC initiative.
However, it has to be noted that there currently aren't some domains of
interest in the specific RDoC matrix, for instance the construct
representingmotor or neurological dysfunction in psychiatric disorders.
Our findingsmight represent a good evidence for a broader array of do-
mains to be included in RDoC.
In conclusion, greater attention should be given to functional out-
comes in patients with a recent onset psychiatric disorder even if they
are not considered at risk for transition to psychosis. In secondary men-
tal health services, a trans-diagnostic approach that takes into account
specific neurocognitive, clinical and neurological dimensions, has the
potential to identify those patients with a common functional trajecto-
ry, despite the clinical heterogeneity. While future studies with larger
sample sizes are needed in order to draw definitive conclusions, our re-
sults provide useful information on a young psychiatric sample, in
which specific therapeutic interventions have the potential to signifi-
cantly limit functional disability.
4.1. Strengths and limitations
Developing site-specific predictor profiles, as proposed here, has a
number of limitations, the need for cross-validation being a primary
one. Second, norms for the RBANS in children and adolescents are not
yet available. Hence, consistent with previous evidence (Holzer et al.,
2007), the raw scores in this study were scaled using the norms for
20–39 year olds also for all participants aged 17–19. Given the short ad-
ministration time and its reliability, the RBANS represents an interesting
screening tool compared tomore time-consuming cognitive assessment
batteries. Third, our ARMS+ detection rate is higher compared to those
reported by previous studies (Rietdijk et al., 2012). However, it is still
consistent with evidence suggesting that: (i) a consecutive screening
in a secondarymental health facility detects more ARMS+ than a refer-
ral at suspicion strategy (54) and (ii) greater and more stable general
psychopathology is associated with a reduction in ARMS false positives
and a higher detection rate (Rietdijk et al., 2012). Similarly, the rate of
psychotic conversion in the identified ARMS sample (25.4%) is consis-
tent with previously published rates of conversion over a 1–2.5 year
time period (Cornblatt et al., 2003). Fourth, the choice of using a
dichotomic outcome (LF vs HF) instead of a continuous one (SOFAS
scores) could represent an additional limitation of the study. However,
given the growing body of literature investigating functional outcomes
in recent-onset psychiatric disorders, we decided to report a result
that could be potentially more easily replicable and comparable across
different research groups. Furthermore, it should be noted that from a
clinical perspective it is the change in SOFASover time,more than its ab-
solute value at follow-up, to be considered more relevant. As highlight-
ed in Section 3.1, patients in the LF group experienced a significant drop
in functioning over time, in contrast to what observed in the HF group.
This suggests that the variables identified in our final predictive models
might help to identify not only those patientswho experienced LF at fol-
low-up, but also those who developed a functional decline. However,
since functional decline was not our primary outcome measure, this
consideration is speculative and only future studies may address this
issue.
Finally, we did not take into account in our analyses some relevant
treatment-related factors, such as acceptance and compliance with
treatment, and other psychosocial factors (e.g. stress, relationship with
families), which could have a significant impact on future outcome in
psychiatric disorders. Future studies should address this issue.
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